Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EGL 003

Next Previous
Drug Profile

EGL 003

Alternative Names: EGL-003

Latest Information Update: 03 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Egle Therapeutics
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 2 inhibitors; Regulatory T-lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 11 Jun 2025 Pharmacokinetics, pharmacodynamics and adverse events data from a preclinical studies in Autoimmune disorders presented at the 26th Annual Congress of the European League Against Rheumatism (EULAR-2025)
  • 17 Mar 2025 Egle Therapeutics expects to file a CTA for EGL 003 for Autoimmune disorders
  • 17 Mar 2025 Egle Therapeutics plans a clinical trial of EGL 003 in Autoimmune disorders (Parenteral), in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top